(Q42551463)

2 November 2017

title

Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats (English)

1 reference

2 November 2017

0 references

Krause BR

1

1 reference

2 November 2017

Barnett BC

2

1 reference

2 November 2017

Essenburg AD

3

1 reference

2 November 2017

Kieft KA

4

1 reference

2 November 2017

Auerbach BJ

5

1 reference

2 November 2017

Bousley R

6

1 reference

2 November 2017

Stanfield R

7

1 reference

2 November 2017

Newton RS

8

1 reference

2 November 2017

Bisgaier CL

9

1 reference

2 November 2017

publication date

1 November 1996

1 reference

2 November 2017

1 reference

2 November 2017

volume

127

1 reference

2 November 2017

issue

1

1 reference

2 November 2017

page(s)

91-101

1 reference

Fibric acids: effects on lipids and lipoprotein metabolism

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Pharmacological approaches to the modulation of plasma cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Mechanism of action of gemfibrozil on lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia Effect of 2,2-dimethyl, 5(2,5-xylyloxy) valeric acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Mechanisms of lipid-lowering agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Portal and aortic blood sampling technique in unrestrained rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Glucocorticoids and triglyceride transport: Effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Human postheparin plasma hepatic lipase activity against triacylglycerol and phospholipid substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Hypocholesterolemic 5-substituted tetrazoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

[Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Differences in the response of Sprague-Dawley and Lewis rats to bezafibrate: the hypolipidemic effect and the induction of peroxisomal enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Effects of gemfibrozil and ketoconazole on human apolipoprotein AI, B and E levels in two hepatoma cell lines, HepG2 and Hep3B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Genetic susceptibility and resistance to diet-induced atherosclerosis and hyperlipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Oxidation of low density lipoproteins greatly enhances their association with lipoprotein lipase anchored to endothelial cell matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Down-regulation of hepatic lipase gene expression and activity by fenofibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Comparison of lifibrol to other lipid-regulating agents in experimental animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Total plasma apo E and high density lipoprotein apo E in survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Effects of gemfibrozil on serum apolipoprotein E distribution in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2896%2905939-4

10.1016/S0021-9150(96)05939-4

7 January 2021

Identifiers

DOI

1 reference

release_ybbh25wl3vcvtbwnw556pap4we

2 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ybbh25wl3vcvtbwnw556pap4we

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference